President Biden's battle against high drug prices, part of the Inflation Reduction Act, is intended to give Medicare patients immediate relief and, in the long term, to regulate what drugmakers charge for their products.
At the 42nd annual event for investors, pharma executives and biotech innovators, the spotlight was on AI, the new GLP-1 class of weight loss drugs, non-profit hospitals and treatment for autoimmune disease.
A new rule, which is set to take effect Jan. 1 and requires PBMs to take most of their "performance fees" at the time prescriptions are filled, is adding to the woes of the independent drugstores it was partly designed to help.
Thousands of patients with autoimmune diseases rely on Humira, at a list price of $6,600 a month, and could benefit from low-cost biosimilars that could save the health care system $9 billion a year, but will PBMs follow suit?
Everyone over the age of 6 months should get the latest COVID-19 booster, a CDC panel recommended Tuesday, which legally obligates commercial insurance coverage of adult vaccines.
The CDC committee, which sets U.S. vaccination policy and helps determine insurance coverage for vaccines, will vote on the question Tuesday as it weighs the benefits of updated vaccines from Pfizer, Moderna, and Novavax.
Even though six drug companies have filed lawsuits to halt the Medicare drug negotiation program, the companies have until Oct. 2 to present data on their drugs to CMS, which will make initial price offers in February.
Patients with early Alzheimer's disease who took lecanemab in a major clinical trial declined an average of five months slower than other subjects over an 18-month period.
In recent months ominous ads about prescription drugs have flooded the TV airwaves - and Congress is paying attention: House and Senate members have launched nine bills that take aim at pharmacy benefit managers.
The main cause, experts agree, is the underlying weakness of the generic drug industry, which are made mostly overseas because U.S. manufacturers are setting their sights instead on high-priced drugs with plump profit margins.
DebugScreen: mobile
{
"author": {
"name": "Arthur Allen",
"webUrl": "/author/profile/arthur-allen/",
"description": "",
"imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
"estimate": 16,
"social": [],
"articles": [
{
"uri": "/2024/02/19/patients-see-first-savings-from-bidens-drug-price-push-as-pharma-lines-up-its-lawyers/",
"title": "Patients start to see savings, ahead of IRA's Medicare drug price negotiations",
"byline": "Arthur Allen",
"kicker": "Update",
"prettyDate": "February 19, 2024",
"timeToRead": "9 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2019/04/paying-pharmacy.jpg",
"width": "617",
"height": "411"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/update/",
"sectionName": "Update"
}
],
"summary": "President Biden's battle against high drug prices, part of the Inflation Reduction Act, is intended to give Medicare patients immediate relief and, in the long term, to regulate what drugmakers charge for their products.",
"body": null
},
{
"uri": "/2024/01/23/what-the-health-care-sector-was-selling-at-the-j-p-morgan-confab/",
"title": "Top trends from JPM Healthcare Conference: What the industry can expect in 2024",
"byline": "Molly Castle Work and Arthur Allen",
"kicker": "Market Insights",
"prettyDate": "January 23, 2024",
"timeToRead": "7 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2024/01/Healthcare-Article-202311150851.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/molly-castle-work/",
"name": "Molly Castle Work"
},
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/market-insights/",
"sectionName": "Market Insights"
}
],
"summary": "At the 42nd annual event for investors, pharma executives and biotech innovators, the spotlight was on AI, the new GLP-1 class of weight loss drugs, non-profit hospitals and treatment for autoimmune disease.",
"body": null
},
{
"uri": "/2023/11/16/biden-administrations-limit-on-drug-industry-middlemen-backfires-pharmacists-say/",
"title": "Biden administration's fee limits on PBMs backfires, say pharmacists",
"byline": "Arthur Allen",
"kicker": "Update",
"prettyDate": "November 16, 2023",
"timeToRead": "7 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/11/Pharmacist-Wolters-Kluwer-Health-Article-202311151540.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/update/",
"sectionName": "Update"
}
],
"summary": "A new rule, which is set to take effect Jan. 1 and requires PBMs to take most of their \"performance fees\" at the time prescriptions are filled, is adding to the woes of the independent drugstores it was partly designed to help.",
"body": null
},
{
"uri": "/2023/09/26/save-billions-or-stick-with-humira-drug-brokers-steer-americans-to-the-costly-choice/",
"title": "Could new biosimilars end Humira's reign as the best-selling drug in history?",
"byline": "Arthur Allen",
"kicker": "Update",
"prettyDate": "September 26, 2023",
"timeToRead": "12 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2019/05/HumiraBloomberg.jpg",
"width": "616",
"height": "373"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/update/",
"sectionName": "Update"
}
],
"summary": "Thousands of patients with autoimmune diseases rely on Humira, at a list price of $6,600 a month, and could benefit from low-cost biosimilars that could save the health care system $9 billion a year, but will PBMs follow suit?",
"body": null
},
{
"uri": "/2023/09/13/cdc-recommends-new-covid-boosters-for-all-but-who-will-pay-for-it/",
"title": "CDC recommends new COVID boosters for all: But who will pay for it?",
"byline": "Arthur Allen",
"kicker": "News",
"prettyDate": "September 13, 2023",
"timeToRead": "7 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/09/Covid-19-vaccine-next-to-a-microscope-Article-202309131013.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/news/",
"sectionName": "News"
}
],
"summary": "Everyone over the age of 6 months should get the latest COVID-19 booster, a CDC panel recommended Tuesday, which legally obligates commercial insurance coverage of adult vaccines.",
"body": null
},
{
"uri": "/2023/09/11/cdcs-big-covid-dilemma-whether-to-recommend-the-new-boosters-for-all-ages/",
"title": "CDC's big COVID dilemma: Whether to recommend the new boosters for all ages",
"byline": "Arthur Allen",
"kicker": "Update",
"prettyDate": "September 11, 2023",
"timeToRead": "7 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/09/Covid-Vaccine-Article-202309110903.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/update/",
"sectionName": "Update"
}
],
"summary": "The CDC committee, which sets U.S. vaccination policy and helps determine insurance coverage for vaccines, will vote on the question Tuesday as it weighs the benefits of updated vaccines from Pfizer, Moderna, and Novavax.",
"body": null
},
{
"uri": "/2023/08/30/drug-price-negotiations-are-on-5-things-to-know-about-the-impact-on-the-industry/",
"title": "Drug price negotiations are on: 5 things to know about the impact on the industry",
"byline": "Arthur Allen, Rachana Pradhan & David Hilzenrath",
"kicker": "Update",
"prettyDate": "August 30, 2023",
"timeToRead": "6 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2020/07/Pharmacist-Article-202007222043.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen-rachana-pradhan/",
"name": "Arthur Allen, Rachana Pradhan"
},
{
"webUrl": "/author/profile/david-hilzenrath/",
"name": "David Hilzenrath"
}
],
"kickerNode": [
{
"uri": "/update/",
"sectionName": "Update"
}
],
"summary": "Even though six drug companies have filed lawsuits to halt the Medicare drug negotiation program, the companies have until Oct. 2 to present data on their drugs to CMS, which will make initial price offers in February.",
"body": null
},
{
"uri": "/2023/08/04/the-real-costs-of-the-new-alzheimers-drug/",
"title": "The real costs of the new alzheimer's drug",
"byline": "Arthur Allen",
"kicker": "News",
"prettyDate": "August 04, 2023",
"timeToRead": "6 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/07/Prescription-drug-costs-Article-202307060846-1.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/news/",
"sectionName": "News"
}
],
"summary": "Patients with early Alzheimer's disease who took lecanemab in a major clinical trial declined an average of five months slower than other subjects over an 18-month period.",
"body": null
},
{
"uri": "/2023/07/17/what-you-need-to-know-about-the-drug-price-fight-in-those-tv-ads/",
"title": "The drug price battle playing out in Congress (and on those TV ads)",
"byline": "Arthur Allen",
"kicker": "Update",
"prettyDate": "July 17, 2023",
"timeToRead": "7 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/07/Prescription-drug-costs-Article-202307060846-1.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/update/",
"sectionName": "Update"
}
],
"summary": "In recent months ominous ads about prescription drugs have flooded the TV airwaves - and Congress is paying attention: House and Senate members have launched nine bills that take aim at pharmacy benefit managers.",
"body": null
},
{
"uri": "/2023/06/26/drugmakers-are-abandoning-cheap-generics-and-now-us-cancer-patients-cant-get-meds/",
"title": "Cancer patients can't get meds as U.S. drugmakers abandon cheap generics",
"byline": "Arthur Allen",
"kicker": "Update",
"prettyDate": "June 26, 2023",
"timeToRead": "10 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2020/03/010-hospital-man-nurse.jpg",
"width": "617",
"height": "411"
},
"authors": [
{
"webUrl": "/author/profile/arthur-allen/",
"name": "Arthur Allen"
}
],
"kickerNode": [
{
"uri": "/update/",
"sectionName": "Update"
}
],
"summary": "The main cause, experts agree, is the underlying weakness of the generic drug industry, which are made mostly overseas because U.S. manufacturers are setting their sights instead on high-priced drugs with plump profit margins.",
"body": null
}
]
}
}
